Atrium Therapeutics, Inc. (RNA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of RNA were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Atrium Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RNA
153 funds and institutions reported RNA shares worth $210M at the end of Q2 2026, about 91% of the company. The largest holder is Sessa Capital IM, L.P. with 8.8%.
Funds and institutions (13F) 91%Everyone else 9%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 1.50M | 8.77% | $20.2M | +172% |
| T. Rowe Price Associates | 1.47M | 8.61% | $19.8M | -5% |
| BlackRock, Inc. | 1.45M | 8.46% | $19.5M | +20% |
| Crcm LP | 1.28M | 7.50% | $17.3M | – |
| Vanguard Capital Management LLC | 730,831 | 4.27% | $9.8M | +17% |
| TIG Advisors, LLC | 561,533 | 3.28% | $7.6M | -8% |
| Arbiter Partners Capital Management LLC | 522,576 | 3.05% | $7M | +127% |
| Cantor Fitzgerald, L. P. | 513,834 | 3.00% | $6.9M | +118% |
| Geode Capital Management, LLC | 386,929 | 2.26% | $5.2M | +21% |
| Two Sigma Investments, LP | 345,481 | 2.02% | $4.6M | +93% |
| Goldman Sachs Group Inc | 310,341 | 1.81% | $4.2M | -11% |
| 683 Capital Management, LLC | 300,000 | 1.75% | $4M | No change |
| State Street Corp | 271,762 | 1.59% | $3.7M | +6% |
| Slotnik Capital, LLC | 237,637 | 1.39% | $3.2M | +31% |
| Weiss Asset Management LP | 219,730 | 1.28% | $3M | -9% |
| Millennium Management LLC | 200,559 | 1.17% | $2.7M | +5% |
| Schonfeld Strategic Advisors LLC | 199,158 | 1.16% | $2.7M | +22% |
| AQR Capital Management LLC | 172,235 | 1.01% | $2.3M | – |
| Nexpoint Asset Management, L.P. | 150,025 | 0.88% | $2M | No change |
| Polar Asset Management Partners Inc. | 150,000 | 0.88% | $2M | +114% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No RNA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RNA short interest
Very high short interest. 21.9% of RNA shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.75M RNA shares were sold short, 21.9% of the shares outstanding, up 0.6% from the report before. At the average daily volume of 233,325 shares, buying them all back would take about 16.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.75M | 21.92% | +1% | 233,325 | 16.1 |
| Oct 15, 2026 | 3.73M | 21.78% | +10% | 288,048 | 12.9 |
| Sep 30, 2026 | 3.40M | 19.85% | -0% | 410,851 | 8.3 |
| Sep 15, 2026 | 3.40M | 19.86% | +1% | 417,130 | 8.2 |
| Aug 31, 2026 | 3.35M | 19.59% | -4% | 169,372 | 19.8 |
| Aug 14, 2026 | 3.48M | 20.35% | -1% | 126,745 | 27.5 |
| Jul 31, 2026 | 3.51M | 20.54% | -2% | 123,798 | 28.4 |
| Jul 15, 2026 | 3.59M | 20.99% | -2% | 202,748 | 17.7 |
| Jun 30, 2026 | 3.66M | 21.38% | +1% | 292,054 | 12.5 |
| Jun 15, 2026 | 3.61M | 21.11% | -1% | 177,756 | 20.3 |
| May 29, 2026 | 3.65M | 21.36% | -2% | 230,736 | 15.8 |
| May 15, 2026 | 3.73M | 21.82% | +9% | 176,203 | 21.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Atrium Therapeutics company events
Atrium Therapeutics filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (control). The latest was on Nov 2, 2026.
- Nov 2, 2026AnnouncementThe Company announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 syndrome during HCMS at the American Heart Association Scientific Sessions 2026, taking… Filing
- Oct 27, 2026AnnouncementAtrium Therapeutics, Inc. issued a press release announcing that the first patient has been dosed in the Company’s Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2… Filing
- Oct 9, 2026AnnouncementAmended an earlier report. As previously disclosed in the Original Form 8-K, on October 7, 2026, the Company entered into a securities purchase agreement with selected investors that qualify as “accredited investors”, as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as… Filing
- Oct 8, 2026AgreementAtrium Therapeutics, Inc. entered into a securities purchase agreement with selected investors that qualify as “accredited investors”, as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended, to sell to the PIPE Investors an aggregate of (i)… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 14, 2026AnnouncementAtrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application allowing the Company to move forward with its CorventisTM Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated… Filing
- May 14, 2026ResultsReleased financial results. Filing
- Feb 27, 2026ControlImmediately prior to the Separation and Distribution, Avidity was the sole stockholder of the Company. Filing
- Feb 26, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold RNA
5 of the 50 well-known investors we track reported holding RNA in their latest 13F filing. The largest position is Ken Griffin's, worth $1.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 218,447 | $1.8M | 0.0% | +223% |
| Israel Englander · Millennium Management | Q3 2026 | 147,661 | $1.2M | 0.0% | -26% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 140,874 | $1.2M | 0.0% | +9% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 28,917 | $239K | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 23,700 | $196K | 0.0% | +58% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RNA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 3.7% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 3.7% |
Questions about Atrium Therapeutics, Inc. (RNA) stock
Who owns the most RNA stock?
The largest reported owner of Atrium Therapeutics, Inc. (RNA) is Sessa Capital IM, L.P., with 8.8% of the company. In total, 153 funds and institutions reported holding RNA at the end of Q2 2026, together about 91% of the shares. See the largest owners.
Are RNA insiders buying or selling?
No RNA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in RNA?
As of Oct 30, 2026, 3.75M RNA shares were sold short, 21.9% of the shares outstanding, up 0.6% from the report before. At the average daily volume of 233,325 shares, buying them all back would take about 16.1 trading days (days to cover). See the history.
Which famous investors hold RNA?
5 of the 50 well-known investors we track reported RNA in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $1.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.